Atossa Therapeutics Inc (ATOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2021 | 03-2021 | 12-2020 | 09-2020 | 06-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -10,577 | -3,538 | -17,828 | -10,345 | -6,854 |
| Depreciation Amortization | 15 | 9 | 47 | 37 | 25 |
| Accounts payable and accrued liabilities | -1,051 | -866 | 1,295 | 389 | 740 |
| Other Working Capital | -1,037 | -1,434 | -112 | -222 | -357 |
| Other Operating Activity | 2,905 | 1,421 | 5,028 | 2,003 | 987 |
| Operating Cash Flow | $-9,745 | $-4,408 | $-11,570 | $-8,138 | $-5,459 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | -9 | -9 | -7 |
| Investing Cash Flow | $N/A | $N/A | $-9 | $-9 | $-7 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 112,624 | 102,428 | 33,619 | 4,686 | 348 |
| Other Financing Activity | 0 | 0 | 4,933 | -14 | 0 |
| Financing Cash Flow | $112,624 | $102,428 | $38,552 | $4,672 | $348 |
| Beginning Cash Position | 39,664 | 39,664 | 12,691 | 12,691 | 12,691 |
| End Cash Position | 142,543 | 137,684 | 39,664 | 9,216 | 7,573 |
| Net Cash Flow | $102,879 | $98,020 | $26,973 | $-3,475 | $-5,118 |
| Free Cash Flow | |||||
| Operating Cash Flow | -9,745 | -4,408 | -11,570 | -8,138 | -5,459 |
| Capital Expenditure | N/A | N/A | -9 | -9 | -7 |
| Free Cash Flow | -9,745 | -4,408 | -11,579 | -8,147 | -5,466 |